WSGR logoWSGR logo
WSGR logo
  • Experience
  • People
  • Insights
  • About Us
  • Careers

  • Practice Areas
  • Industries

  • Corporate
  • Intellectual Property
  • Litigation
  • Regulatory

  • Broker Dealer
  • Capital Markets
  • Corporate Governance
  • Emerging Companies
  • Employee Benefits and Compensation
  • Energy and Infrastructure
  • Finance and Structured Finance
  • Fund Formation
  • Greater China
  • Investment Adviser
  • Mergers & Acquisitions
  • Private Equity
  • Public Company Representation
  • Real Estate
  • Restructuring
  • Shareholder Activism
  • Tax
  • U.S. Expansion

  • Special Purpose Acquisition Companies (SPACs)

  • Environmental, Social, and Governance

  • Distributed Generation, Energy Efficiency and Storage, and Microgrids
  • Energy Regulation
  • Project Development and Transactions
  • Sustainability and Climate Solutions

  • U.S. Expansion Library and Resources

  • Patents and Innovations
  • Post-Grant Review
  • Technology Transactions
  • Trademark and Advertising

  • Arbitration
  • Board and Internal Investigations
  • Class Action Litigation
  • Commercial Litigation
  • Consumer Litigation
  • Corporate Governance Litigation
  • Employment Litigation
  • Government Investigations
  • Internet Strategy and Litigation
  • Patent Litigation
  • Securities Litigation
  • Supreme Court and Appellate Practice
  • Trade Secret Litigation
  • Trademark and Copyright Litigation
  • Trial
  • White Collar Crime

  • Antitrust and Competition
  • Committee on Foreign Investment in the U.S. (CFIUS)
  • Export Control and Sanctions
  • FCPA and Anti-Corruption
  • FDA Regulatory, Healthcare, and Consumer Products
  • Federal Trade Commission
  • National Security
  • Privacy and Cybersecurity

  • Antitrust and Intellectual Property
  • Antitrust Civil Enforcement
  • Antitrust Compliance and Business Strategy
  • Antitrust Criminal Enforcement
  • Antitrust Merger Clearance
  • Antitrust Litigation
  • European Competition Law
  • Third-Party Merger and Non-Merger Antitrust Representation

  • Anti-Money Laundering
  • Foreign Ownership, Control, or Influence (FOCI)
  • Team Telecom

  • Aviation
  • Biotech
  • Blockchain and Cryptocurrency
  • Clean Technology
  • Communications and Networking
  • Consumer Products and Services
  • Data Storage and Cloud
  • Digital Health
  • Digital Media and Entertainment
  • Electronic Gaming
  • Energy
  • Financial Services
  • FoodTech and AgTech
  • Fintech
  • Global Generics
  • Internet
  • Life Sciences
  • Medical Devices
  • Mobile Devices
  • Mobility
  • Semiconductors
  • Software

  • Offices
  • Events
  • Pro Bono
  • Community
  • Our Diversity
  • Our Values
  • Board of Directors
  • Management Team
  • Executive Advisory Program

  • Austin
  • Beijing
  • Boston
  • Brussels
  • Hong Kong
  • London
  • Los Angeles
  • New York
  • Palo Alto
  • Salt Lake City
  • San Diego
  • San Francisco
  • Seattle
  • Shanghai
  • SOMA
  • Washington, D.C.
  • Wilmington, DE

  • Attorney Recruiting
  • Professional Staff
  • Recruiting Contacts

  • Experienced Attorneys
  • Law Students

  • Apply Online
  • Associates Committee
  • Benefits Snapshot
  • Career Management Center
  • Compensation and Benefits
  • Contacts
  • Launch
  • Mentoring and Feedback
  • NALP Forms
  • Training and Development
  • Work Assignments
  • Your School Alumni

  • Contacts
  • First Year Academy
  • Launch and Accelerate
  • NALP Forms
  • Summer Program
  • Tech Degrees
  • Join a Winning Team
  • Law School Recruiting
  • Your School Alumni

  • Current Openings
  • Employee Benefits Summary
  • Patent Agents & Scientific Advisors

Emerging Companies

Open PDF
  • Introducing Neuron, the Digital Home for Your Legal Needs

    The Emerging Companies Practice (ECP) is excited to announce the launch of Neuron, a new platform that streamlines, automates, and digitizes the typical legal processes along a start-up’s journey – from incorporation to fundraising to exit. Clients will experience seamless integration of documentation, third-party data sources, and direct collaboration with their legal team.

  • Trusted Counsel to Start-Ups and Entrepreneurs

    As the country's leading firm representing venture-backed companies, Wilson Sonsini has counseled thousands of start-ups and entrepreneurs who are starting new businesses, advising them on company formation, equity structures, investor negotiations, IP rights, and other issues.

  • Perennial Leader for Venture Financings

    Wilson Sonsini has consistently ranked No. 1 for the number of venture capital deals handled each year, dating back to the 1980s.

  • U.S. Expansion Expertise

    We've advised hundreds of non-U.S. companies that have elected to enter the U.S. market, whether to expand, raise investment capital, or pursue a key transaction.

Since the firm's inception in the early days of Silicon Valley, Wilson Sonsini has been privileged to help lay the groundwork for some of the world's most innovative technology, life sciences, and growth companies. As the nation's leading law firm representing venture-backed companies, we have counseled thousands of entrepreneurs starting new businesses, advising on the formation of companies, equity structures, negotiations with investors, intellectual property rights, and other issues vital to their success.

An Interdisciplinary Approach

We take an interdisciplinary approach to counseling entrepreneurs and young companies, offering deep expertise in such vital areas as:

  • Corporate Governance
  • Patents and Innovations
  • Employee Benefits and Compensation
  • Employment Litigation
  • Tax and Tax Equity
  • Real Estate
  • Finance and Structured Finance
  • Fund Formation
  • Mergers & Acquisitions

This interdisciplinary approach, along with the breadth and depth of our practice, allows us to serve as a strategic advisor through each stage of a private company's growth. In addition, we have a number of business processes and proprietary knowledge management systems in place that enable all of our attorneys to leverage the collective experience and skills of the firm, ensuring maximum effectiveness and efficiencies for our clients.

A Network for Entrepreneurs

Our attorneys have seen countless ventures—launched with little more than a promising idea and the passion of their founders—grow into highly successful, mature companies. The firm has grown as well; currently, we represent more than 300 public and 3,000 private companies. But our commitment to entrepreneurs remains resolute, and we always are looking for new ways to serve their needs.

We provide entrepreneurs with the information and opportunities they need to develop into the next generation of industry leaders. The firm's resources are extended to all entrepreneurs and emerging company executives who establish a relationship with the firm. For example, we invite contacts to networking events, workshops, and other programs covering a wide range of topics designed to help entrepreneurs focus their ideas, develop a business strategy, build the right relationships, and access capital.

U.S. Expansion

Our attorneys have advised hundreds of non-U.S. start-up and growth-stage technology companies—including clients based in the U.K., Israel, and other EMEA countries; South and Central America; and Greater Asia—that have decided to enter the U.S. market, whether to expand, raise investment capital, or pursue a key transaction.

We also work closely with key local stakeholders in those regions—investors, accelerators, incubators, professional advisors, strategic partners, and government economic development agencies—to provide home market support on U.S. matters and ensure that companies have the right teams around them to succeed in the U.S.

To learn more about our U.S. expansion practice, please click here.

Overview

Since the firm's inception in the early days of Silicon Valley, Wilson Sonsini has been privileged to help lay the groundwork for some of the world's most innovative technology, life sciences, and growth companies. As the nation's leading law firm representing venture-backed companies, we have counseled thousands of entrepreneurs starting new businesses, advising on the formation of companies, equity structures, negotiations with investors, intellectual property rights, and other issues vital to their success.

An Interdisciplinary Approach

We take an interdisciplinary approach to counseling entrepreneurs and young companies, offering deep expertise in such vital areas as:

  • Corporate Governance
  • Patents and Innovations
  • Employee Benefits and Compensation
  • Employment Litigation
  • Tax and Tax Equity
  • Real Estate
  • Finance and Structured Finance
  • Fund Formation
  • Mergers & Acquisitions

This interdisciplinary approach, along with the breadth and depth of our practice, allows us to serve as a strategic advisor through each stage of a private company's growth. In addition, we have a number of business processes and proprietary knowledge management systems in place that enable all of our attorneys to leverage the collective experience and skills of the firm, ensuring maximum effectiveness and efficiencies for our clients.

A Network for Entrepreneurs

Our attorneys have seen countless ventures—launched with little more than a promising idea and the passion of their founders—grow into highly successful, mature companies. The firm has grown as well; currently, we represent more than 300 public and 3,000 private companies. But our commitment to entrepreneurs remains resolute, and we always are looking for new ways to serve their needs.

We provide entrepreneurs with the information and opportunities they need to develop into the next generation of industry leaders. The firm's resources are extended to all entrepreneurs and emerging company executives who establish a relationship with the firm. For example, we invite contacts to networking events, workshops, and other programs covering a wide range of topics designed to help entrepreneurs focus their ideas, develop a business strategy, build the right relationships, and access capital.

U.S. Expansion

Our attorneys have advised hundreds of non-U.S. start-up and growth-stage technology companies—including clients based in the U.K., Israel, and other EMEA countries; South and Central America; and Greater Asia—that have decided to enter the U.S. market, whether to expand, raise investment capital, or pursue a key transaction.

We also work closely with key local stakeholders in those regions—investors, accelerators, incubators, professional advisors, strategic partners, and government economic development agencies—to provide home market support on U.S. matters and ensure that companies have the right teams around them to succeed in the U.S.

To learn more about our U.S. expansion practice, please click here.

Client Highlights
Wilson Sonsini Advises Cambridge Epigenetix on IP Matters Related to $88 Million Series D
On November 2, 2021, Cambridge Epigenetix, a life sciences tools and technology company revolutionizing genome sequencing, announced the signing of an $88 million Series D financing, bringing the total funds raised to date to $146 million. Temasek led the Series D round with participation from new investors including Third Point and existing investors such as GV, New Science Ventures, Ahren Innovation Capital, and Sequoia. Wilson Sonsini Goodrich & Rosati advised Cambridge Epigenetix on IP matters related to the transaction.
Client Highlights
Wilson Sonsini Advises Merge on $15 Million Series A Funding
On November 3, 2021, Merge, an integrations platform that focuses on B2B use cases, announced that it has raised a $15 million Series A funding round led by Addition, with participation from existing investor NEA and a number of angel investors. Wilson Sonsini Goodrich & Rosati advised Merge on the transaction.

According to Merge co-founder Gil Feig, the fundraise allows the company to commit to growing not just its product and team, but its partnerships, a critical part of the business. “With this round, we’re continuing on our mission to revolutionize how every B2B company approaches its integrations strategy,” he wrote. In addition to the Series A funding, Merge announced partnerships with HR provider BambooHR and application tracking system Lever.

When Merge announced its seed funding with NEA in May 2021, there were 100 companies on its platform; that figure is now more than 600, including several public companies. The company has released several product features since then, including better logs, enhanced webhooks, CSV upload, SAML SSO, and a single-tenant offering; built out integrations for platforms like Oracle Taleo, Jobvite, and Workday HRIS; and grown its team to 20 people.

The Wilson Sonsini team that advised Merge on the transaction included Seth Helfgott, Rob Broderick, Daniel Xo, Adam Shevell, and Matt Staples.

For more information, please see the announcement on Merge’s blog and this TechCrunch article.
Client Highlights
Wilson Sonsini Advises Arcaea, Inc. on $78 Million Series A Financing
On October 27, 2021, Arcaea, a company launched on the Ginkgo Bioworks platform, announced its $78 million Series A to build a new, regenerative future for the beauty industry through expressive biology—where biology is used as a creative tool for self-expression. Arcaea, formerly known as Kalo Ingredients, LLC,  will grow new ingredients and product experiences for beauty by leveraging technology such as DNA sequencing, biological engineering, and fermentation to activate unique storytelling. Wilson Sonsini Goodrich & Rosati advised Arcaea on intellectual property, patent, licensing and contracts, including its spinout from Gingko Bioworks.

The Series A funding comes from a consortium of strategic and financial investors including Cascade Investment L.L.C., Viking Global, CHANEL, Givaudan, and Wittington Ventures. The financing will enable Arcaea to initiate multiple technical programs across key categories in beauty to develop a pipeline of ingredients and brand launches and create a world of previously unimaginable possibilities in beauty, such as: a fragrance that no one on earth has ever smelled before; proteins that can memorize hair styles; contouring through skincare and not just makeup; and biological filters that protect skin from the elements.
Client Highlights
Firm Advises General Atlantic on CinCor Pharma’s $143 Million Series B Financing
On October 12, 2021, CinCor Pharma, Inc. announced the completion of a $143 million Series B financing. The financing was led by General Atlantic, a leading global growth equity firm, with participation from new investors Perceptive Advisors, BVF Partners, venBio Partners, Adage Capital Management, Omega Funds, Rock Springs Capital, RTW Investments, Lilly Asia Ventures, and Sixty Degree Capital, alongside existing investors Sofinnova Investments, Sofinnova Partners, 5AM Ventures and CinRx. Wilson Sonsini Goodrich & Rosati represented General Atlantic on the transaction.
Client Highlights
Wilson Sonsini Represents Novo Holdings on BIOMILQ, Inc.’s $21 Million Series A Financing
On October, 20, 2021, North Carolina-based mammary biotechnology company BIOMILQ, Inc., announced the successful close of $21 million in Series A financing, which will enable their acceleration of bringing cell-cultured human milk to market. Leading the fundraise are Danish life science investor Novo Holdings and clean tech leader Breakthrough Energy Ventures. Additional support comes from Blue Horizon, Spero Ventures, Digitalis Ventures, Green Generation Fund, Alexandria and Gaingels. Wilson Sonsini Goodrich & Rosati represented Novo Holdings on the transaction.
Client Highlights
Wilson Sonsini Advises ReCode Therapeutics on $80 Million Series B
On October 21, 2021, ReCode Therapeutics, a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary LNP delivery platform, announced the closing of an $80 million Series B financing round co-led by Pfizer Ventures and EcoR1 Capital. New investors include Sanofi Ventures, funds managed by Tekla Capital Management LLC, Superstring Capital, and NS Investment. Existing investors who participated included OrbiMed, Vida Ventures, MPM Capital, Colt Ventures, Hunt Technology Ventures, L.P., and Osage University Partners (OUP). The proceeds from the Series B financing will be used to drive ReCode’s lead programs in primary ciliary dyskinesia (PCD) and cystic fibrosis (CF) into human clinical studies, expand the pipeline of treatments for patients with life-limiting genetic respiratory diseases, advance its LNP platform for organ-specific delivery of RNA and gene correction therapies, and increase internal manufacturing capabilities.
View All
Insights
Client Highlights
Wilson Sonsini Advises Cambridge Epigenetix on IP Matters Related to $88 Million Series D
On November 2, 2021, Cambridge Epigenetix, a life sciences tools and technology company revolutionizing genome sequencing, announced the signing of an $88 million Series D financing, bringing the total funds raised to date to $146 million. Temasek led the Series D round with participation from new investors including Third Point and existing investors such as GV, New Science Ventures, Ahren Innovation Capital, and Sequoia. Wilson Sonsini Goodrich & Rosati advised Cambridge Epigenetix on IP matters related to the transaction.
Client Highlights
Wilson Sonsini Advises Merge on $15 Million Series A Funding
On November 3, 2021, Merge, an integrations platform that focuses on B2B use cases, announced that it has raised a $15 million Series A funding round led by Addition, with participation from existing investor NEA and a number of angel investors. Wilson Sonsini Goodrich & Rosati advised Merge on the transaction.

According to Merge co-founder Gil Feig, the fundraise allows the company to commit to growing not just its product and team, but its partnerships, a critical part of the business. “With this round, we’re continuing on our mission to revolutionize how every B2B company approaches its integrations strategy,” he wrote. In addition to the Series A funding, Merge announced partnerships with HR provider BambooHR and application tracking system Lever.

When Merge announced its seed funding with NEA in May 2021, there were 100 companies on its platform; that figure is now more than 600, including several public companies. The company has released several product features since then, including better logs, enhanced webhooks, CSV upload, SAML SSO, and a single-tenant offering; built out integrations for platforms like Oracle Taleo, Jobvite, and Workday HRIS; and grown its team to 20 people.

The Wilson Sonsini team that advised Merge on the transaction included Seth Helfgott, Rob Broderick, Daniel Xo, Adam Shevell, and Matt Staples.

For more information, please see the announcement on Merge’s blog and this TechCrunch article.
Client Highlights
Wilson Sonsini Advises Arcaea, Inc. on $78 Million Series A Financing
On October 27, 2021, Arcaea, a company launched on the Ginkgo Bioworks platform, announced its $78 million Series A to build a new, regenerative future for the beauty industry through expressive biology—where biology is used as a creative tool for self-expression. Arcaea, formerly known as Kalo Ingredients, LLC,  will grow new ingredients and product experiences for beauty by leveraging technology such as DNA sequencing, biological engineering, and fermentation to activate unique storytelling. Wilson Sonsini Goodrich & Rosati advised Arcaea on intellectual property, patent, licensing and contracts, including its spinout from Gingko Bioworks.

The Series A funding comes from a consortium of strategic and financial investors including Cascade Investment L.L.C., Viking Global, CHANEL, Givaudan, and Wittington Ventures. The financing will enable Arcaea to initiate multiple technical programs across key categories in beauty to develop a pipeline of ingredients and brand launches and create a world of previously unimaginable possibilities in beauty, such as: a fragrance that no one on earth has ever smelled before; proteins that can memorize hair styles; contouring through skincare and not just makeup; and biological filters that protect skin from the elements.
Client Highlights
Firm Advises General Atlantic on CinCor Pharma’s $143 Million Series B Financing
On October 12, 2021, CinCor Pharma, Inc. announced the completion of a $143 million Series B financing. The financing was led by General Atlantic, a leading global growth equity firm, with participation from new investors Perceptive Advisors, BVF Partners, venBio Partners, Adage Capital Management, Omega Funds, Rock Springs Capital, RTW Investments, Lilly Asia Ventures, and Sixty Degree Capital, alongside existing investors Sofinnova Investments, Sofinnova Partners, 5AM Ventures and CinRx. Wilson Sonsini Goodrich & Rosati represented General Atlantic on the transaction.
Client Highlights
Wilson Sonsini Represents Novo Holdings on BIOMILQ, Inc.’s $21 Million Series A Financing
On October, 20, 2021, North Carolina-based mammary biotechnology company BIOMILQ, Inc., announced the successful close of $21 million in Series A financing, which will enable their acceleration of bringing cell-cultured human milk to market. Leading the fundraise are Danish life science investor Novo Holdings and clean tech leader Breakthrough Energy Ventures. Additional support comes from Blue Horizon, Spero Ventures, Digitalis Ventures, Green Generation Fund, Alexandria and Gaingels. Wilson Sonsini Goodrich & Rosati represented Novo Holdings on the transaction.
Client Highlights
Wilson Sonsini Advises ReCode Therapeutics on $80 Million Series B
On October 21, 2021, ReCode Therapeutics, a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary LNP delivery platform, announced the closing of an $80 million Series B financing round co-led by Pfizer Ventures and EcoR1 Capital. New investors include Sanofi Ventures, funds managed by Tekla Capital Management LLC, Superstring Capital, and NS Investment. Existing investors who participated included OrbiMed, Vida Ventures, MPM Capital, Colt Ventures, Hunt Technology Ventures, L.P., and Osage University Partners (OUP). The proceeds from the Series B financing will be used to drive ReCode’s lead programs in primary ciliary dyskinesia (PCD) and cystic fibrosis (CF) into human clinical studies, expand the pipeline of treatments for patients with life-limiting genetic respiratory diseases, advance its LNP platform for organ-specific delivery of RNA and gene correction therapies, and increase internal manufacturing capabilities.
View All
WSGR Events
Phoenix 2022: The Medical Device and Diagnostic Conference for Chief Executive Officers
As the organizers of the Phoenix Conference, we take a great deal of pride in our annual event, which has long provided medical device and diagnostic executives with an unrivaled experience that helps to inform and shape company strategy for the years ahead. At the same time, our top priority is the health and safety of everyone involved in our program. As a result, in light of the continuing COVID-19 pandemic, we have decided to postpone the 2021 Phoenix Conference.
Speaking Engagements
Crossing the Valley of Death: Lab to IPO and Lab to Acquisition
Wilson Sonsini is pleased to support Design Technologies as they present, Crossing the Valley of Death: Lab to IPO and Lab to Acquisition. The series provides a view of the parties involved in early stage academic spin outs. They 'tell a story' of the early stages of their venture and share their journey crossing the chasm to lead ventures from academia to the public market.
Affiliated Programs
American Diabetes Association's 26th Annual Leaders Forum: HealthTech Showcase and Thought Leader Discussions
Wilson Sonsini is proud to sponsor ADA's 2021 Silicon Valley Leaders Forum HealthTech Showcase.
Affiliated Programs
LaunchBio Founders Circle, Durham: Attracting VCs, How to Stand Out from the Crowd
Wilson Sonsini is pleased to support LaunchBio’s Founders Circle, Attracting VCs, How to Stand Out from the Crowd. Attracting and engaging with the right VCs and partners is critical to translating science into an impactful patient solution. Learn what VCs are looking for in early-stage life science companies, making company and asset(s) attractive, how to create and drive value, and how VCs can help with more than money.
Affiliated Programs
Clinical Trial Diversity: Closing The Gap to Achieve Health Equity
Wilson Sonsini is pleased to support Athena’s Life Sciences Special Interest Group as they present Clinical Trial Diversity, Closing the Gap to Achieve Health Equity. As diversity, equity, inclusion and accessibility increasingly become top priorities for organizations worldwide, the healthcare sector still lags considerably. This session will offer a dynamic discussion of why diversity is essential for medical developments including clinical trials, precision genomics and DNA sequencing.
Affiliated Programs
LaunchBio Founders Circle, Boston: Leveraging Outsourced Partners in 2022, How to Scale Faster with Less Risk
Wilson Sonsini is pleased to support LaunchBio’s Founders Circle, Leveraging Outsourced Partners in 2022, How to Scale Faster with Less Risk. Early-stage biotech companies have special operational, regulatory, skill, and financial considerations. Experience and quality of care are crucial characteristics when trusting parts of research to an outsourced service. Understanding when and how to leverage outsourced partners can help biotech startups achieve preclinical milestones faster and increase investor attractiveness.
View All
Events
WSGR Events
Phoenix 2022: The Medical Device and Diagnostic Conference for Chief Executive Officers
As the organizers of the Phoenix Conference, we take a great deal of pride in our annual event, which has long provided medical device and diagnostic executives with an unrivaled experience that helps to inform and shape company strategy for the years ahead. At the same time, our top priority is the health and safety of everyone involved in our program. As a result, in light of the continuing COVID-19 pandemic, we have decided to postpone the 2021 Phoenix Conference.
Speaking Engagements
Crossing the Valley of Death: Lab to IPO and Lab to Acquisition
Wilson Sonsini is pleased to support Design Technologies as they present, Crossing the Valley of Death: Lab to IPO and Lab to Acquisition. The series provides a view of the parties involved in early stage academic spin outs. They 'tell a story' of the early stages of their venture and share their journey crossing the chasm to lead ventures from academia to the public market.
Affiliated Programs
American Diabetes Association's 26th Annual Leaders Forum: HealthTech Showcase and Thought Leader Discussions
Wilson Sonsini is proud to sponsor ADA's 2021 Silicon Valley Leaders Forum HealthTech Showcase.
Affiliated Programs
LaunchBio Founders Circle, Durham: Attracting VCs, How to Stand Out from the Crowd
Wilson Sonsini is pleased to support LaunchBio’s Founders Circle, Attracting VCs, How to Stand Out from the Crowd. Attracting and engaging with the right VCs and partners is critical to translating science into an impactful patient solution. Learn what VCs are looking for in early-stage life science companies, making company and asset(s) attractive, how to create and drive value, and how VCs can help with more than money.
Affiliated Programs
Clinical Trial Diversity: Closing The Gap to Achieve Health Equity
Wilson Sonsini is pleased to support Athena’s Life Sciences Special Interest Group as they present Clinical Trial Diversity, Closing the Gap to Achieve Health Equity. As diversity, equity, inclusion and accessibility increasingly become top priorities for organizations worldwide, the healthcare sector still lags considerably. This session will offer a dynamic discussion of why diversity is essential for medical developments including clinical trials, precision genomics and DNA sequencing.
Affiliated Programs
LaunchBio Founders Circle, Boston: Leveraging Outsourced Partners in 2022, How to Scale Faster with Less Risk
Wilson Sonsini is pleased to support LaunchBio’s Founders Circle, Leveraging Outsourced Partners in 2022, How to Scale Faster with Less Risk. Early-stage biotech companies have special operational, regulatory, skill, and financial considerations. Experience and quality of care are crucial characteristics when trusting parts of research to an outsourced service. Understanding when and how to leverage outsourced partners can help biotech startups achieve preclinical milestones faster and increase investor attractiveness.
View All
Megan J. Baier
Partner
New York
Megan represents technology and life sciences clients in corporate transactional matters.
  • Corporate
View Profile
Mark Bass
Partner
Washington, D.C.
Mark Bass is a partner in the Washington, D.C., office of Wilson Sonsini Goodrich & Rosati, where he works with public and private technology companies at all stages of growth. He also represents venture capital funds, private equity firms, and investment banks in financings and public offerings.
  • Corporate
View Profile
Mark B. Baudler
Partner
Palo Alto
Mark is a corporate law veteran, having advised start-ups and mature public companies for over 20 years.
  • Corporate
View Profile
Braden L. Berg
Partner
San Francisco
Brady L. Berg is a partner at Wilson Sonsini Goodrich & Rosati, where he focuses on corporate and securities law, including venture capital transactions, public offerings, and mergers and acquisitions with an emphasis on technology start-ups.
  • Corporate
View Profile
Steven V. Bernard
Partner
Palo Alto

Steve has represented non-U.S. and domestic companies in U.S. IPOs, global securities offerings, cross-border M&A, and SEC compliance for more than 25 years.

  • Corporate
View Profile
Mark A. Bertelsen
Partner
Palo Alto
Mark is a veteran Silicon Valley attorney who has represented innovative companies that are today's technology leaders.
  • Corporate
View Profile
Josh Beser
Partner
New York
Joshua (Josh) Beser is a corporate partner in the New York office of Wilson Sonsini Goodrich & Rosati, where he brings over a decade of executive-level, in-house operating experience at consumer brands and technology and life sciences companies.
  • Corporate
View Profile
Richard C. Blake
Partner
Palo Alto
Richard has a comprehensive corporate law background, with extensive experience in public offerings.
  • Corporate
View Profile
Adam Shaun Bloom
Partner
Palo Alto
Adam's corporate law practice focuses on complex transactions and deals involving novel structures.
  • Corporate
View Profile
Steven E. Bochner
Partner
Palo Alto

Steve has over 39 years of corporate law experience, serving as lead counsel for many of Silicon Valley's most prominent companies.

 

 

 

  • Corporate
View Profile
View All
People
Megan J. Baier
Partner
New York
Megan represents technology and life sciences clients in corporate transactional matters.
  • Corporate
View Profile
Mark Bass
Partner
Washington, D.C.
Mark Bass is a partner in the Washington, D.C., office of Wilson Sonsini Goodrich & Rosati, where he works with public and private technology companies at all stages of growth. He also represents venture capital funds, private equity firms, and investment banks in financings and public offerings.
  • Corporate
View Profile
Mark B. Baudler
Partner
Palo Alto
Mark is a corporate law veteran, having advised start-ups and mature public companies for over 20 years.
  • Corporate
View Profile
Braden L. Berg
Partner
San Francisco
Brady L. Berg is a partner at Wilson Sonsini Goodrich & Rosati, where he focuses on corporate and securities law, including venture capital transactions, public offerings, and mergers and acquisitions with an emphasis on technology start-ups.
  • Corporate
View Profile
Steven V. Bernard
Partner
Palo Alto

Steve has represented non-U.S. and domestic companies in U.S. IPOs, global securities offerings, cross-border M&A, and SEC compliance for more than 25 years.

  • Corporate
View Profile
Mark A. Bertelsen
Partner
Palo Alto
Mark is a veteran Silicon Valley attorney who has represented innovative companies that are today's technology leaders.
  • Corporate
View Profile
Josh Beser
Partner
New York
Joshua (Josh) Beser is a corporate partner in the New York office of Wilson Sonsini Goodrich & Rosati, where he brings over a decade of executive-level, in-house operating experience at consumer brands and technology and life sciences companies.
  • Corporate
View Profile
Richard C. Blake
Partner
Palo Alto
Richard has a comprehensive corporate law background, with extensive experience in public offerings.
  • Corporate
View Profile
Adam Shaun Bloom
Partner
Palo Alto
Adam's corporate law practice focuses on complex transactions and deals involving novel structures.
  • Corporate
View Profile
Steven E. Bochner
Partner
Palo Alto

Steve has over 39 years of corporate law experience, serving as lead counsel for many of Silicon Valley's most prominent companies.

 

 

 

  • Corporate
View Profile
View All

Using the above link to Wilson Sonsini's Term Sheet Generator,  you can generate a venture financing term sheet based on your responses to an online questionnaire. It also has an informational component, with basic tutorials and annotations on financing terms. This term sheet generator is a modified version of a tool that Wilson Sonsini uses internally, which comprises one part of a suite of document automation tools that we use to generate start-up and venture-financing-related documents.

Please Note

Progress will not be saved. Any generated documents will open in Word. An .xml answer file may also be exported.

Because it has been designed as a generic tool that takes into account a number of options, this version of the term sheet generator is fairly expansive and includes significantly more detail than would likely be found in a customized application.

Contacts

Please direct any general questions regarding the term sheet generator to Tony Kikuta (akikuta@wsgr.com) or Yokum Taku (ytaku@wsgr.com) at (650) 493-9300. For technical issues, please contact Wilson Sonsini's Help Desk at (650) 493-9300 (ext. 6161).

Other Resources

The Term Sheet Generator is part of a suite of automation tools that the firm uses to generate start-up and venture financing-related documents. In addition to the Term Sheet Generator, Wilson Sonsini offers a public version of a Convertible Note Term Sheet Generator for equity venture financings, which you can access through the above tab. The firm also offers other free online resources for entrepreneurs, including our Entrepreneurs Reports, our quarterly newsletters that present data on venture financings in which the firm was involved, with the objective of identifying relevant trends in activity and valuation levels for the U.S. venture capital industry in general. Visit our ECP website to view the most current and past issues of our Entrepreneurs Report.

Terms and Conditions

By using Wilson Sonsini's Term Sheet Generator, you agree to the Terms and Conditions below.

No Attorney-Client Relationship

The Wilson Sonsini Term Sheet Generator, including the online questionnaire and annotations (the TSG), and the form of memorandum of terms generated by the TSG (the Term Sheet) have been prepared by Wilson Sonsini Goodrich & Rosati (Wilson Sonsini) for general informational purposes only and do not constitute advertising, a solicitation, or legal advice. Neither the availability, operation, transmission, receipt, nor use of the TSG or the Term Sheet is intended to create, or constitutes formation of, an attorney-client relationship or any other special relationship or privilege. You should not rely upon the TSG or the Term Sheet for any purpose without seeking legal advice from licensed attorneys in the relevant state(s).

Privacy Matters

As part of the normal operation of the underlying software, the TSG temporarily stores information that you have entered (as well as a temporary copy of the Term Sheet) so that the underlying software can operate as designed. By using the TSG, you confirm that you have authority to share any information that you furnish. We disclaim any and all liability in connection with the collection, use, or disclosure of the information furnished by you or otherwise collected by the TSG. Please note that we cannot guarantee the security of any information transmitted to us over the internet. Please also refer to the Privacy Policy that generally governs the use of Wilson Sonsini's website.

Compliance with Laws

You agree to use the TSG and the Term Sheet in compliance with all applicable laws, including applicable securities laws, and you agree to indemnify and hold Wilson Sonsini harmless from and against any and all claims, damages, losses, or obligations arising from your failure to comply.

Disclaimer of Liability

THE TSG AND THE TERM SHEET ARE PROVIDED AS-IS WITH NO REPRESENTATIONS OR WARRANTIES, EITHER EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND NONINFRINGEMENT. YOU ASSUME COMPLETE RESPONSIBILITY AND RISK FOR USE OF THE TSG AND THE TERM SHEET. Some jurisdictions do not allow the exclusion of implied warranties, so the above exclusion may not apply to you.

Wilson Sonsini expressly disclaims all liability, loss, or risk incurred as a direct or indirect consequence of the use of the TSG or the Term Sheet. By using the TSG or the Term Sheet, you waive any rights or claims you may have against Wilson Sonsini in connection therewith. The information contained in the TSG and the Term Sheet is provided only as general information and may not reflect the most current market and legal developments and may not address all relevant business or legal issues; accordingly, information in the TSG or the Term Sheet is not promised or guaranteed to be correct or complete. Further, Wilson Sonsini does not necessarily endorse, and is not responsible for, any third-party content that may be accessed through the TSG and the Term Sheet.

Wilson Sonsini at its sole discretion may choose to change the terms, conditions, and operation of the TSG and the Term Sheet at any time. Wilson Sonsini, in its sole discretion, reserves the right to refuse to provide you access to the TSG and the Term Sheet. You agree that Wilson Sonsini shall not be liable to you for loss or damages that may result from our refusal to provide access to the TSG or the Term Sheet.

Use by Agents

You agree that, if an agent (e.g., an attorney, an employee, etc.) uses the TSG or the Term Sheet on your behalf, you are nonetheless bound as a principal by all terms and conditions herein.

Circular 230 Compliance

To ensure compliance with requirements imposed by the IRS, we inform you that any U.S. federal tax information contained in this communication (including any attachments) is not intended or written to be used, and cannot be used, for the purpose of:

  1. avoiding penalties under the Internal Revenue Code, or
  2. promoting, marketing, or recommending to another party any transaction or matter addressed herein. You should seek advice based on your particular circumstances from a tax advisor.

 

Term Sheet Generator

Using the above link to Wilson Sonsini's Term Sheet Generator,  you can generate a venture financing term sheet based on your responses to an online questionnaire. It also has an informational component, with basic tutorials and annotations on financing terms. This term sheet generator is a modified version of a tool that Wilson Sonsini uses internally, which comprises one part of a suite of document automation tools that we use to generate start-up and venture-financing-related documents.

Please Note

Progress will not be saved. Any generated documents will open in Word. An .xml answer file may also be exported.

Because it has been designed as a generic tool that takes into account a number of options, this version of the term sheet generator is fairly expansive and includes significantly more detail than would likely be found in a customized application.

Contacts

Please direct any general questions regarding the term sheet generator to Tony Kikuta (akikuta@wsgr.com) or Yokum Taku (ytaku@wsgr.com) at (650) 493-9300. For technical issues, please contact Wilson Sonsini's Help Desk at (650) 493-9300 (ext. 6161).

Other Resources

The Term Sheet Generator is part of a suite of automation tools that the firm uses to generate start-up and venture financing-related documents. In addition to the Term Sheet Generator, Wilson Sonsini offers a public version of a Convertible Note Term Sheet Generator for equity venture financings, which you can access through the above tab. The firm also offers other free online resources for entrepreneurs, including our Entrepreneurs Reports, our quarterly newsletters that present data on venture financings in which the firm was involved, with the objective of identifying relevant trends in activity and valuation levels for the U.S. venture capital industry in general. Visit our ECP website to view the most current and past issues of our Entrepreneurs Report.

Terms and Conditions

By using Wilson Sonsini's Term Sheet Generator, you agree to the Terms and Conditions below.

No Attorney-Client Relationship

The Wilson Sonsini Term Sheet Generator, including the online questionnaire and annotations (the TSG), and the form of memorandum of terms generated by the TSG (the Term Sheet) have been prepared by Wilson Sonsini Goodrich & Rosati (Wilson Sonsini) for general informational purposes only and do not constitute advertising, a solicitation, or legal advice. Neither the availability, operation, transmission, receipt, nor use of the TSG or the Term Sheet is intended to create, or constitutes formation of, an attorney-client relationship or any other special relationship or privilege. You should not rely upon the TSG or the Term Sheet for any purpose without seeking legal advice from licensed attorneys in the relevant state(s).

Privacy Matters

As part of the normal operation of the underlying software, the TSG temporarily stores information that you have entered (as well as a temporary copy of the Term Sheet) so that the underlying software can operate as designed. By using the TSG, you confirm that you have authority to share any information that you furnish. We disclaim any and all liability in connection with the collection, use, or disclosure of the information furnished by you or otherwise collected by the TSG. Please note that we cannot guarantee the security of any information transmitted to us over the internet. Please also refer to the Privacy Policy that generally governs the use of Wilson Sonsini's website.

Compliance with Laws

You agree to use the TSG and the Term Sheet in compliance with all applicable laws, including applicable securities laws, and you agree to indemnify and hold Wilson Sonsini harmless from and against any and all claims, damages, losses, or obligations arising from your failure to comply.

Disclaimer of Liability

THE TSG AND THE TERM SHEET ARE PROVIDED AS-IS WITH NO REPRESENTATIONS OR WARRANTIES, EITHER EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND NONINFRINGEMENT. YOU ASSUME COMPLETE RESPONSIBILITY AND RISK FOR USE OF THE TSG AND THE TERM SHEET. Some jurisdictions do not allow the exclusion of implied warranties, so the above exclusion may not apply to you.

Wilson Sonsini expressly disclaims all liability, loss, or risk incurred as a direct or indirect consequence of the use of the TSG or the Term Sheet. By using the TSG or the Term Sheet, you waive any rights or claims you may have against Wilson Sonsini in connection therewith. The information contained in the TSG and the Term Sheet is provided only as general information and may not reflect the most current market and legal developments and may not address all relevant business or legal issues; accordingly, information in the TSG or the Term Sheet is not promised or guaranteed to be correct or complete. Further, Wilson Sonsini does not necessarily endorse, and is not responsible for, any third-party content that may be accessed through the TSG and the Term Sheet.

Wilson Sonsini at its sole discretion may choose to change the terms, conditions, and operation of the TSG and the Term Sheet at any time. Wilson Sonsini, in its sole discretion, reserves the right to refuse to provide you access to the TSG and the Term Sheet. You agree that Wilson Sonsini shall not be liable to you for loss or damages that may result from our refusal to provide access to the TSG or the Term Sheet.

Use by Agents

You agree that, if an agent (e.g., an attorney, an employee, etc.) uses the TSG or the Term Sheet on your behalf, you are nonetheless bound as a principal by all terms and conditions herein.

Circular 230 Compliance

To ensure compliance with requirements imposed by the IRS, we inform you that any U.S. federal tax information contained in this communication (including any attachments) is not intended or written to be used, and cannot be used, for the purpose of:

  1. avoiding penalties under the Internal Revenue Code, or
  2. promoting, marketing, or recommending to another party any transaction or matter addressed herein. You should seek advice based on your particular circumstances from a tax advisor.

 

Using the above link to Wilson Sonsini's Convertible Note Term Sheet Generator,  you can generate a convertible note term sheet based on your responses to an online questionnaire. It also has an educational component, with basic tutorials and annotations.

This term sheet generator is a modified version of a tool that Wilson Sonsini uses internally, which comprises one part of a suite of document automation tools that we use to generate start-up and venture-financing-related documents.

Please Note

Progress will not be saved. Any generated documents will open in Word. An .xml answer file may also be exported.

Because it has been designed to account for a number of options, this version of the term sheet generator is fairly expansive and includes more detail than would likely be found in a customized application.

Contacts

Please direct any general questions regarding the term sheet generator to Tony Kikuta (akikuta@wsgr.com) or Yokum Taku (ytaku@wsgr.com) at (650) 493-9300. For technical issues, please contact Wilson Sonsini's Help Desk at (650) 493-9300 (ext. 6161).

Other Resources

The Convertible Note Term Sheet Generator is part of a suite of automation tools that the firm uses to generate start-up and venture financing-related documents. In addition to the Convertible Note Term Sheet Generator, Wilson Sonsini offers a public version of a Term Sheet Generator for equity venture financings, which you can access through the above tab. The firm also offers other free online resources for entrepreneurs, including our Entrepreneurs Reports, our quarterly newsletters that present data on venture financings in which the firm was involved, with the objective of identifying relevant trends in activity and valuation levels for the U.S. venture capital industry in general. Visit our ECP website to view the most current and past issues of our Entrepreneurs Report.

Terms and Conditions

By using Wilson Sonsini's Term Sheet Generator (Convertible Notes), you agree to the Terms and Conditions below.

No Attorney-Client Relationship

The Wilson Sonsini Convertible Note Term Sheet Generator, including the online questionnaire and annotations (the TSG), and the form of memorandum of terms generated by the TSG (the Term Sheet) have been prepared by Wilson Sonsini Goodrich & Rosati (Wilson Sonsini) for general informational purposes only and do not constitute advertising, a solicitation or legal advice. Neither the availability, operation, transmission, receipt nor use of the TSG or the Term Sheet is intended to create, or constitutes formation of, an attorney-client relationship or any other special relationship or privilege. You should not rely upon the TSG or the Term Sheet for any purpose without seeking legal advice from licensed attorneys in the relevant state(s).

Privacy Matters

As part of the normal operation of the underlying software, the TSG temporarily stores information that you have entered (as well as a temporary copy of the Term Sheet) so that the underlying software can operate as designed. By using the TSG, you confirm that you have authority to share any information that you furnish. We disclaim any and all liability in connection with the collection, use or disclosure of the information furnished by you or otherwise collected by the TSG. Please note that we cannot guarantee the security of any information transmitted to us over the internet. Please also refer to the Privacy Policy that generally governs the use of Wilson Sonsini's website.

Compliance with Laws

You agree to use the TSG and the Term Sheet in compliance with all applicable laws, including applicable securities laws, and you agree to indemnify and hold Wilson Sonsini harmless from and against any and all claims, damages, losses, or obligations arising from your failure to comply.

Disclaimer of Liability

THE TSG AND THE TERM SHEET ARE PROVIDED AS-IS WITH NO REPRESENTATIONS OR WARRANTIES, EITHER EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND NONINFRINGEMENT. YOU ASSUME COMPLETE RESPONSIBILITY AND RISK FOR USE OF THE TSG AND THE TERM SHEET. Some jurisdictions do not allow the exclusion of implied warranties, so the above exclusion may not apply to you.

Wilson Sonsini expressly disclaims all liability, loss or risk incurred as a direct or indirect consequence of the use of the TSG or the Term Sheet. By using the TSG or the Term Sheet, you waive any rights or claims you may have against Wilson Sonsini in connection therewith. The information contained in the TSG and the Term Sheet is provided only as general information and may not reflect the most current market and legal developments and may not address all relevant business or legal issues; accordingly, information in the TSG or the Term Sheet is not promised or guaranteed to be correct or complete. Further, Wilson Sonsini does not necessarily endorse, and is not responsible for, any third-party content that may be accessed through the TSG and the Term Sheet.

Wilson Sonsini at its sole discretion may choose to change the terms, conditions, and operation of the TSG and the Term Sheet at any time. Wilson Sonsini, in its sole discretion, reserves the right to refuse to provide you access to the TSG and the Term Sheet. You agree that Wilson Sonsini shall not be liable to you for loss or damages that may result from our refusal to provide access to the TSG or the Term Sheet.

Use by Agents

You agree that, if an agent (e.g., an attorney, an employee, etc.) uses the TSG or the Term Sheet on your behalf, you are nonetheless bound as a principal by all terms and conditions herein.

Circular 230 Compliance

To ensure compliance with requirements imposed by the IRS, we inform you that any U.S. federal tax information contained in this communication (including any attachments) is not intended or written to be used, and cannot be used, for the purpose of:

  1. avoiding penalties under the Internal Revenue Code, or
  2. promoting, marketing, or recommending to another party any transaction or matter addressed herein. You should seek advice based on your particular circumstances from a tax advisor.
Convertible Note Term Sheet Generator

Using the above link to Wilson Sonsini's Convertible Note Term Sheet Generator,  you can generate a convertible note term sheet based on your responses to an online questionnaire. It also has an educational component, with basic tutorials and annotations.

This term sheet generator is a modified version of a tool that Wilson Sonsini uses internally, which comprises one part of a suite of document automation tools that we use to generate start-up and venture-financing-related documents.

Please Note

Progress will not be saved. Any generated documents will open in Word. An .xml answer file may also be exported.

Because it has been designed to account for a number of options, this version of the term sheet generator is fairly expansive and includes more detail than would likely be found in a customized application.

Contacts

Please direct any general questions regarding the term sheet generator to Tony Kikuta (akikuta@wsgr.com) or Yokum Taku (ytaku@wsgr.com) at (650) 493-9300. For technical issues, please contact Wilson Sonsini's Help Desk at (650) 493-9300 (ext. 6161).

Other Resources

The Convertible Note Term Sheet Generator is part of a suite of automation tools that the firm uses to generate start-up and venture financing-related documents. In addition to the Convertible Note Term Sheet Generator, Wilson Sonsini offers a public version of a Term Sheet Generator for equity venture financings, which you can access through the above tab. The firm also offers other free online resources for entrepreneurs, including our Entrepreneurs Reports, our quarterly newsletters that present data on venture financings in which the firm was involved, with the objective of identifying relevant trends in activity and valuation levels for the U.S. venture capital industry in general. Visit our ECP website to view the most current and past issues of our Entrepreneurs Report.

Terms and Conditions

By using Wilson Sonsini's Term Sheet Generator (Convertible Notes), you agree to the Terms and Conditions below.

No Attorney-Client Relationship

The Wilson Sonsini Convertible Note Term Sheet Generator, including the online questionnaire and annotations (the TSG), and the form of memorandum of terms generated by the TSG (the Term Sheet) have been prepared by Wilson Sonsini Goodrich & Rosati (Wilson Sonsini) for general informational purposes only and do not constitute advertising, a solicitation or legal advice. Neither the availability, operation, transmission, receipt nor use of the TSG or the Term Sheet is intended to create, or constitutes formation of, an attorney-client relationship or any other special relationship or privilege. You should not rely upon the TSG or the Term Sheet for any purpose without seeking legal advice from licensed attorneys in the relevant state(s).

Privacy Matters

As part of the normal operation of the underlying software, the TSG temporarily stores information that you have entered (as well as a temporary copy of the Term Sheet) so that the underlying software can operate as designed. By using the TSG, you confirm that you have authority to share any information that you furnish. We disclaim any and all liability in connection with the collection, use or disclosure of the information furnished by you or otherwise collected by the TSG. Please note that we cannot guarantee the security of any information transmitted to us over the internet. Please also refer to the Privacy Policy that generally governs the use of Wilson Sonsini's website.

Compliance with Laws

You agree to use the TSG and the Term Sheet in compliance with all applicable laws, including applicable securities laws, and you agree to indemnify and hold Wilson Sonsini harmless from and against any and all claims, damages, losses, or obligations arising from your failure to comply.

Disclaimer of Liability

THE TSG AND THE TERM SHEET ARE PROVIDED AS-IS WITH NO REPRESENTATIONS OR WARRANTIES, EITHER EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND NONINFRINGEMENT. YOU ASSUME COMPLETE RESPONSIBILITY AND RISK FOR USE OF THE TSG AND THE TERM SHEET. Some jurisdictions do not allow the exclusion of implied warranties, so the above exclusion may not apply to you.

Wilson Sonsini expressly disclaims all liability, loss or risk incurred as a direct or indirect consequence of the use of the TSG or the Term Sheet. By using the TSG or the Term Sheet, you waive any rights or claims you may have against Wilson Sonsini in connection therewith. The information contained in the TSG and the Term Sheet is provided only as general information and may not reflect the most current market and legal developments and may not address all relevant business or legal issues; accordingly, information in the TSG or the Term Sheet is not promised or guaranteed to be correct or complete. Further, Wilson Sonsini does not necessarily endorse, and is not responsible for, any third-party content that may be accessed through the TSG and the Term Sheet.

Wilson Sonsini at its sole discretion may choose to change the terms, conditions, and operation of the TSG and the Term Sheet at any time. Wilson Sonsini, in its sole discretion, reserves the right to refuse to provide you access to the TSG and the Term Sheet. You agree that Wilson Sonsini shall not be liable to you for loss or damages that may result from our refusal to provide access to the TSG or the Term Sheet.

Use by Agents

You agree that, if an agent (e.g., an attorney, an employee, etc.) uses the TSG or the Term Sheet on your behalf, you are nonetheless bound as a principal by all terms and conditions herein.

Circular 230 Compliance

To ensure compliance with requirements imposed by the IRS, we inform you that any U.S. federal tax information contained in this communication (including any attachments) is not intended or written to be used, and cannot be used, for the purpose of:

  1. avoiding penalties under the Internal Revenue Code, or
  2. promoting, marketing, or recommending to another party any transaction or matter addressed herein. You should seek advice based on your particular circumstances from a tax advisor.
Recent Insights
Client Highlights
Wilson Sonsini Advises Cambridge Epigenetix on IP Matters Related to $88 Million Series D
On November 2, 2021, Cambridge Epigenetix, a life sciences tools and technology company revolutionizing genome sequencing, announced the signing of an $88 million Series D financing, bringing the total funds raised to date to $146 million. Temasek led the Series D round with participation from new investors including Third Point and existing investors such as GV, New Science Ventures, Ahren Innovation Capital, and Sequoia. Wilson Sonsini Goodrich & Rosati advised Cambridge Epigenetix on IP matters related to the transaction.
Learn More
Client Highlights
Wilson Sonsini Advises Merge on $15 Million Series A Funding
On November 3, 2021, Merge, an integrations platform that focuses on B2B use cases, announced that it has raised a $15 million Series A funding round led by Addition, with participation from existing investor NEA and a number of angel investors. Wilson Sonsini Goodrich & Rosati advised Merge on the transaction.

According to Merge co-founder Gil Feig, the fundraise allows the company to commit to growing not just its product and team, but its partnerships, a critical part of the business. “With this round, we’re continuing on our mission to revolutionize how every B2B company approaches its integrations strategy,” he wrote. In addition to the Series A funding, Merge announced partnerships with HR provider BambooHR and application tracking system Lever.

When Merge announced its seed funding with NEA in May 2021, there were 100 companies on its platform; that figure is now more than 600, including several public companies. The company has released several product features since then, including better logs, enhanced webhooks, CSV upload, SAML SSO, and a single-tenant offering; built out integrations for platforms like Oracle Taleo, Jobvite, and Workday HRIS; and grown its team to 20 people.

The Wilson Sonsini team that advised Merge on the transaction included Seth Helfgott, Rob Broderick, Daniel Xo, Adam Shevell, and Matt Staples.

For more information, please see the announcement on Merge’s blog and this TechCrunch article.
Learn More
View All
Recent Events
WSGR Events
Phoenix 2022: The Medical Device and Diagnostic Conference for Chief Executive Officers
As the organizers of the Phoenix Conference, we take a great deal of pride in our annual event, which has long provided medical device and diagnostic executives with an unrivaled experience that helps to inform and shape company strategy for the years ahead. At the same time, our top priority is the health and safety of everyone involved in our program. As a result, in light of the continuing COVID-19 pandemic, we have decided to postpone the 2021 Phoenix Conference.
Learn More
Speaking Engagements
Crossing the Valley of Death: Lab to IPO and Lab to Acquisition
Wilson Sonsini is pleased to support Design Technologies as they present, Crossing the Valley of Death: Lab to IPO and Lab to Acquisition. The series provides a view of the parties involved in early stage academic spin outs. They 'tell a story' of the early stages of their venture and share their journey crossing the chasm to lead ventures from academia to the public market.
Learn More
View All
Newsletters
The Entrepreneurs Report - Q1 2021
We are pleased to present the Q1 2021 edition of The Entrepreneurs Report, which features a range of data on venture financing transactions in which the firm was involved during the first quarter of 2021. This latest issue also includes a feature on the recent launch of our Emerging Companies Practice site and data from Beauhurst on UK equity investment in Q1 2021.
Read The Entrepreneurs Report
  • people
  • insights
  • about us
  • careers
  • Binder
  • Alumni
  • Mailing List Signup
  • Client/Employee Login
  • Client FTP Portal
  • Privacy Policy
  • Terms of Use
  • Accessibility
WSGR logo
Twitter
LinkedIn
Facebook
Instagram
Copyright © 2021 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.